The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 27692854 |
100 |
N-Arylsulfonyl-a-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity. |
Boehringer Ingelheim Pharmaceuticals |
| 25101488 |
50 |
Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. |
Bristol-Myers Squibb |
| 24332486 |
35 |
Structure activity relationships of fused bicyclic and urea derivatives of spirocyclic compounds as potent CCR1 antagonists. |
Astrazeneca |
| 23707259 |
98 |
The discovery of BMS-457, a potent and selective CCR1 antagonist. |
Bristol-Myers Squibb |
| 23659855 |
36 |
Design, synthesis and structure activity relationships of spirocyclic compounds as potent CCR1 antagonists. |
Astrazeneca |
| 23414842 |
16 |
Spirocyclic compounds, potent CCR1 antagonists. |
Astrazeneca |
| 23374868 |
76 |
1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists. |
Chemocentryx |
| 20627722 |
89 |
Identification of a sulfonamide series of CCR2 antagonists. |
Glaxosmithkline |
| 23142617 |
57 |
Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part I. |
Astrazeneca |
| 23079519 |
86 |
In vivo activity of an azole series of CCR2 antagonists. |
Glaxosmithkline |
| 22957890 |
174 |
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors. |
University of Copenhagen |
| 23075267 |
85 |
Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis. |
Bristol-Myers Squibb |
| 22931505 |
69 |
Chemokine receptor antagonists. |
National Heart and Lung Institute |
| 18313297 |
107 |
Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series. |
Deltagen Research Laboratories (Former Combichem) |
| 18329267 |
136 |
Identification of novel series of human CCR1 antagonists. |
Tanabe Research Laboratories Usa |
| 17483457 |
58 |
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. |
Abbott Laboratories |
| 16198561 |
99 |
Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis. |
Novartis Institutes For Biomedical Research |
| 10579830 |
98 |
Discovery of novel non-peptide CCR1 receptor antagonists. |
Berlex Biosciences |
| 14505678 |
21 |
Design and synthesis of novel CCR3 antagonists. |
Roche Palo Alto |
| 22104149 |
1 |
Potent adjuvantic activity of a CCR1-agonistic bis-quinoline. |
University of Kansas |
| 22047688 |
51 |
CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood. |
Glaxosmithkline |
| 21940167 |
12 |
Design and synthesis of a library of chemokine antagonists. |
Novartis Institutes of Biomedical Research |
| 21341682 |
37 |
Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function. |
Telik |
| 20708929 |
13 |
Novel pyrrolidine heterocycles as CCR1 antagonists. |
Ligand Pharmaceuticals |
| 20591666 |
66 |
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase. |
Università |
| 20297846 |
33 |
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. |
Genzyme |
| 19674898 |
31 |
Spiropiperidine CCR5 antagonists. |
Roche Palo Alto |
| 19183043 |
36 |
Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists. |
Pharmacopeia |
| 19014885 |
32 |
Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist. |
Roche Palo Alto |
| 17446072 |
68 |
Structure-activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists. |
Tanabe Research Laboratories |
| 17383873 |
10 |
Piperazinyl CCR1 antagonists--optimization of human liver microsome stability. |
Pfizer |
| 16698264 |
37 |
Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists. |
Merck Research Laboratories |
| 16539392 |
29 |
Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety. |
Takeda Pharmaceutical |
| 15771462 |
125 |
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency. |
Pharmaceutical Research Institute |
| 15081003 |
38 |
Novel CCR1 antagonists with improved metabolic stability. |
Pfizer |
| 15081002 |
33 |
Potent small molecule CCR1 antagonists. |
Pfizer |
| 15081001 |
17 |
The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template. |
Pfizer |
| 12166951 |
146 |
Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists. |
Bristol-Myers Squibb |
| 11720852 |
51 |
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection. |
Merck Research Laboratories |
| 11720851 |
52 |
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection. |
Merck Research Laboratories |
| 11354381 |
19 |
Discovery of a novel CCR3 selective antagonist. |
Banyu Tsukuba Research Institute |
| 11311066 |
76 |
Design, synthesis, and discovery of a novel CCR1 antagonist. |
Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories |
| 11206474 |
51 |
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes. |
Merck Research Laboratories |
| 11140734 |
8 |
Inhibition of RANTES/CCR1-mediated chemotaxis by cosalane and related compounds. |
National Cancer Istitute-Frederick Cancer Research and Development Center |
| 10821717 |
29 |
Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. |
Takeda Chemical Industries |
| 30455146 |
52 |
Discovery and optimization of pyrazole amides as antagonists of CCR1. |
Boehringer Ingelheim Pharmaceuticals |
| 30256641 |
142 |
Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2. |
Leiden University |
| 30595446 |
63 |
Identification of novel azaindazole CCR1 antagonist clinical candidates. |
Boehringer Ingelheim Pharmaceuticals |
| 23409871 |
48 |
Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists. |
Glaxosmithkline |
| 30098865 |
60 |
Identification of a novel series of potent and selective CCR6 inhibitors as biological probes. |
Takeda Pharmaceutical |
| 29631962 |
252 |
Identification and biological evaluation of thiazole-based inverse agonists of ROR?t. |
Phenex Pharmaceuticals |
| 28094913 |
2 |
Inhibition of Pax2 Transcription Activation with a Small Molecule that Targets the DNA Binding Domain. |
University of Michigan |
Search and Browse
